News

Founded in 2001, Selexis is a scientific pioneer in mammalian (suspension-adapted CHO-K1) cell line generation that helps partners to develop innovative therapies. Its cell line expression technologies can

OMS721, a human monoclonal antibody selectively targets MASP-2 which expands to mannan-binding lectin-associated serine protease-2, the effector enzyme of the lectin pathway of the complement system. The breakthrough

Tanezumab is an investigational humanized monoclonal antibody, which can selectively target, bind and inhibit nerve growth factor (NGF). Through inhibiting NGF, tanezumab will enable to prevent pain signals produced

The data are being presented in an invited presentation at the European League Against Rheumatism’s Annual European Congress of Rheumatology (EULAR 2017) in Madrid this week. The new

The results showed that a single dose of REMD-477 substantially reduced daily insulin requirements and glucose levels without increasing hypoglycemia (low blood glucose levels) in patients. The randomized,

Under the agreement, TeneoBio will leverage Selexis’ proprietary SUREtechnology Platform to develop and optimize the cellular expression of multi-specific UniAbs that were discovered using TeneoBio’s proprietary sequence-based TeneoSeek discovery engine

Under the agreement, Numerate will drive discovery programs aimed at identifying clinical candidates for use in Takeda’s core therapeutic areas: oncology, gastroenterology, and central nervous system disorders. The

The company plans to discontinue the HCV candidate development, after the completion of the one remaining clinical study that is expected in July this year. Regulus has decided to terminate

The removal was sought after concerns that the risks associated with consuming the drug outweighed its benefits, stated the FDA. In fact, it marks the first time that the